Clinical trial
Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA)
NCT00777127 is registered in ClinicalTrials.gov with MEDA Pharma GmbH & Co. KG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA)
- Lead sponsor
- MEDA Pharma GmbH & Co. KG
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 31, 2008
- Completion date
- November 30, 2012
- Enrollment
- 258 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.
actinic keratosis